These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21274120)

  • 1. Research on old drugs: expand indications.
    Russell AL
    Can Fam Physician; 1985 Nov; 31():2037. PubMed ID: 21274120
    [No Abstract]   [Full Text] [Related]  

  • 2. Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead.
    Shah RR; Stonier PD
    J Clin Pharm Ther; 2019 Feb; 44(1):6-22. PubMed ID: 30218625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of follow-on drugs and indications on the WHO Essential Drug List.
    Cohen J; Cabanilla L; Sosnov J
    J Clin Pharm Ther; 2006 Dec; 31(6):585-92. PubMed ID: 17176363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting new indications of compounds with a network pharmacology approach: Liuwei Dihuang Wan as a case study.
    Wang YY; Bai H; Zhang RZ; Yan H; Ning K; Zhao XM
    Oncotarget; 2017 Nov; 8(55):93957-93968. PubMed ID: 29212201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks.
    Liu H; Song Y; Guan J; Luo L; Zhuang Z
    BMC Bioinformatics; 2016 Dec; 17(Suppl 17):539. PubMed ID: 28155639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014.
    Rathi VK; Wang B; Ross JS; Downing NS; Kesselheim AS; Gray ST
    Otolaryngol Head Neck Surg; 2017 Apr; 156(4):683-692. PubMed ID: 28116974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pediatric Orphan Drug Indications: 2010-2018.
    Kimmel L; Conti RM; Volerman A; Chua KP
    Pediatrics; 2020 Apr; 145(4):. PubMed ID: 32127360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of thrombotic and cardiovascular disorders in the new millenium.
    Fareed J; Hoppensteadt DA; Bick RL
    Clin Appl Thromb Hemost; 2003 Apr; 9(2):101-8. PubMed ID: 12812377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implantable cardioverter-defibrillator: present and future indications.
    Block M; Scheld H; Breithardt G
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():141-7. PubMed ID: 8734176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Qualitative Study on the Differences Between Trial Populations and the Approved Therapeutic Indications of Antineoplastic Agents by 3 Regulatory Agencies From 2010 to 2018.
    Sumi E; Asada R; Lu Y; Ito-Ihara T; Grimes KV
    Clin Ther; 2020 Feb; 42(2):305-320.e0. PubMed ID: 32008723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: reliability of compendia methods for off-label oncology indications.
    Abernethy AP; Raman G; Balk EM; Hammond JM; Orlando LA; Wheeler JL; Lau J; McCrory DC
    Ann Intern Med; 2009 Mar; 150(5):336-43. PubMed ID: 19221366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using drug knowledgebase information to distinguish between look-alike-sound-alike drugs.
    Cheng CM; Salazar A; Amato MG; Lambert BL; Volk LA; Schiff GD
    J Am Med Inform Assoc; 2018 Jul; 25(7):872-884. PubMed ID: 29800453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prescribing for unlabeled indications.
    Serradell J; Galle B
    HMO Pract; 1993 Mar; 7(1):44-7. PubMed ID: 10125083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inferior Vena Cava Filters: Guidelines, Best Practice, and Expanding Indications.
    DeYoung E; Minocha J
    Semin Intervent Radiol; 2016 Jun; 33(2):65-70. PubMed ID: 27247472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A critical appraisal of indications for the implantable cardioverter defibrillator (ICD).
    Cannom DS
    Clin Cardiol; 1992 May; 15(5):369-72. PubMed ID: 1623658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigating the landscape of US orphan product approvals.
    Miller KL; Lanthier M
    Orphanet J Rare Dis; 2018 Oct; 13(1):183. PubMed ID: 30348193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review.
    Wang B; Kesselheim AS
    BMJ; 2015 Sep; 351():h4679. PubMed ID: 26400844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs for rare diseases: influence of orphan designation status on price.
    Picavet E; Dooms M; Cassiman D; Simoens S
    Appl Health Econ Health Policy; 2011 Jul; 9(4):275-9. PubMed ID: 21682354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repositioning by applying 'expression profiles' generated by integrating chemical structure similarity and gene semantic similarity.
    Tan F; Yang R; Xu X; Chen X; Wang Y; Ma H; Liu X; Wu X; Chen Y; Liu L; Jia X
    Mol Biosyst; 2014 May; 10(5):1126-38. PubMed ID: 24603772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.